Legend Biotech Corporation (FRA:9LB)
Germany · Delayed Price · Currency is EUR 14.60
-0.30 (-2.01%)
At close: Jan 30, 2026
Legend Biotech Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -239.7 | -177.03 | -518.25 | -446.35 | -403.58 | -266.37 |
Depreciation & Amortization | 23.52 | 21.59 | 18.56 | 18.39 | 12.54 | 9.74 |
Other Amortization | 1.77 | 1.77 | 1.9 | - | 1.38 | 4.21 |
Loss (Gain) From Sale of Assets | 0 | 0 | 0.23 | 0.48 | 0.97 | 0.06 |
Asset Writedown & Restructuring Costs | 4.42 | 4.42 | - | - | - | - |
Loss (Gain) From Sale of Investments | - | - | -0.66 | -0.59 | - | -0.05 |
Stock-Based Compensation | 63.05 | 68.94 | 47.68 | 34.34 | 20.16 | 4.76 |
Other Operating Activities | 80.24 | -83.85 | 128.61 | 5.24 | 8.15 | 45.44 |
Change in Accounts Receivable | -0.07 | 93.75 | -98.98 | 50.32 | 24.59 | -45 |
Change in Inventory | -6.91 | -17.21 | -12.71 | -13.89 | 0.05 | -0.64 |
Change in Accounts Payable | 66.34 | 14.06 | -50.2 | 72.45 | 1.81 | -4.35 |
Change in Unearned Revenue | -40.95 | -49.61 | 100.02 | 6.18 | 0.08 | 2.45 |
Change in Other Net Operating Assets | -121.78 | -20.87 | -9.46 | 72.16 | 135.39 | 26.75 |
Operating Cash Flow | -170.07 | -144.03 | -393.28 | -201.28 | -198.47 | -223.01 |
Capital Expenditures | -18.61 | -14.11 | -20.08 | -20.93 | -42.2 | -26.25 |
Sale of Property, Plant & Equipment | - | - | - | - | 0 | 0 |
Sale (Purchase) of Intangibles | - | - | -2.64 | -1.35 | -3.21 | -4.03 |
Investment in Securities | 37.46 | -784.56 | 204.58 | -41.36 | -147.88 | 25.56 |
Other Investing Activities | -35.58 | -51.88 | -89.07 | -13.45 | -1.71 | -19.45 |
Investing Cash Flow | -16.73 | -850.54 | 92.79 | -77.09 | -194.98 | -24.17 |
Short-Term Debt Repaid | - | - | - | - | - | -0 |
Long-Term Debt Repaid | - | -4.02 | -3.76 | -2.6 | -1.42 | -2.6 |
Total Debt Repaid | -3.58 | -4.02 | -3.76 | -2.6 | -1.42 | -2.61 |
Net Debt Issued (Repaid) | -3.58 | -4.02 | -3.76 | -2.6 | -1.42 | -2.61 |
Issuance of Common Stock | 3.59 | 9.72 | 795.25 | 380.57 | 628.08 | 463.55 |
Other Financing Activities | - | - | - | - | - | -2.51 |
Financing Cash Flow | 0.01 | 5.7 | 791.49 | 377.98 | 626.66 | 618.88 |
Foreign Exchange Rate Adjustments | 6.4 | -2.09 | 0.68 | -2.51 | 0.03 | 0.62 |
Net Cash Flow | -180.38 | -990.96 | 491.68 | 97.09 | 233.25 | 372.33 |
Free Cash Flow | -188.68 | -158.14 | -413.36 | -222.21 | -240.66 | -249.26 |
Free Cash Flow Margin | -20.76% | -25.21% | -144.97% | -189.91% | -349.67% | -332.34% |
Free Cash Flow Per Share | -1.02 | -0.86 | -2.35 | -1.40 | -1.71 | -2.11 |
Cash Interest Paid | 1.77 | 1.77 | 1.39 | 0.53 | 0.14 | 0.2 |
Cash Income Tax Paid | 17.88 | 1.55 | -0.31 | -3.71 | -0.56 | -7.11 |
Levered Free Cash Flow | -157 | -38.58 | -441.19 | -202.66 | -122.84 | -169.98 |
Unlevered Free Cash Flow | -144.56 | -25.07 | -427.57 | -195.91 | -122.28 | -169.86 |
Change in Working Capital | -103.38 | 20.12 | -71.32 | 187.21 | 161.91 | -20.79 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.